Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Radioiodine Spill-Induced Radiation Dermatitis.","authors":"Mahbod Jafarvand, Christiaan Schiepers, Magnus Dalhbom, Angela Castellanos Rieger, Peter George Maliha, Shadfar Bahri","doi":"10.2967/jnumed.125.270585","DOIUrl":"https://doi.org/10.2967/jnumed.125.270585","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET Imaging of Tumor-Associated Macrophage Dynamics and Response to Clinical Treatment for Potential Translation.","authors":"Gyu Seong Heo, Alexandria Li, Joan Tao, Jesse Meir Zaretsky, Deborah Sultan, Lisa Detering, Divangana Lahad, Hannah Luehmann, Xiaohui Zhang, Xiuli Zhang, Xuefeng Gao, Rajiu Venkatesan, Julie Belmar, Robert Crowder, Peter Voller, Akash Mallady, Ying-Hwey Nai, Robert Gropler, Richard Laforest, Chieh-Yu Lin, Shunqiang Li, Farrokh Dehdashti, Sidharth Venkata Puram, Yongjian Liu","doi":"10.2967/jnumed.126.272473","DOIUrl":"https://doi.org/10.2967/jnumed.126.272473","url":null,"abstract":"<p><p>Tumor-associated macrophages (TAMs) are an important component of the tumor microenvironment (TME). The abundance and distribution of TAMs significantly affect the immune responses of TME to determine the tumor progression and treatment response of solid tumors such as head and neck squamous cell carcinoma (HNSCC). Molecular characterization of human HNSCC specimens and mouse models has identified CD163 as a unique biomarker for TAMs in HNSCC. The goal of this study was to determine the dynamic changes of CD163-positive TAMs in HNSCC progression and treatment response to assess the potential of a CD163 targeted radiotracer, ⁶⁴Cu-ICT-01, in detecting CD163-positive TAMs for translation in HNSCC. <b>Methods:</b> We assessed the capability of ⁶⁴Cu-ICT-01 for noninvasive imaging of CD163-positive TAMs using PET. We determined its targeting specificity in multiple mouse HNSCC models to track the progression of tumors. We assessed its sensitivity in tracking variations of CD163-positive TAMs and correlation with tumor volumes after clinical treatment. We also measured its binding to CD163-positive TAMs upregulated on human HNSCC tissues. <b>Results:</b> ⁶⁴Cu-ICT-01 PET specifically determined the spatiotemporal distribution of CD163-positive TAMs in a MOC1 cell line model and patient-derived xenograft HNSCC models. CD163 PET sensitively tracked the dynamics of CD163-positive TAMs after clinical treatment. Its tumor binding correlated with CD163 expression levels and the volumes of tumors. In human HNSCC specimens, ⁶⁴Cu-ICT-01 showed strong and specific binding to human CD163. <b>Conclusion:</b> ⁶⁴Cu-ICT-01 demonstrated accurate targeting of CD163 in both mouse tumor models and human HNSCC tissues. CD163 PET has great potential to be a noninvasive biomarker to measure TAM activities within TME, monitor treatment response, and optimize treatment strategy.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of ¹⁷⁷Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations.","authors":"Kritika Subramanian, Joseph R Osborne","doi":"10.2967/jnumed.126.272700","DOIUrl":"https://doi.org/10.2967/jnumed.126.272700","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT and Multiparametric MRI Before Prostate Biopsy.","authors":"Michael Froehner, Klaus Zöphel","doi":"10.2967/jnumed.126.272393","DOIUrl":"https://doi.org/10.2967/jnumed.126.272393","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Cost-Effectiveness of ¹⁷⁷Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations\".","authors":"Kemal C Gogebakan, Natalia Kunst, Alireza Ghodsi, Lukas Owens, Amir Iravani, Ruth Etzioni","doi":"10.2967/jnumed.126.273360","DOIUrl":"https://doi.org/10.2967/jnumed.126.273360","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on FDA Approval Pathways.","authors":"Shaojun Zhu, Bella Whalen, Thomas A Hope","doi":"10.2967/jnumed.126.273516","DOIUrl":"https://doi.org/10.2967/jnumed.126.273516","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Suspected Tumor Recurrence with Epidermal Growth Factor Receptor-Targeted [⁸⁹Zr]Zr-Panitumumab PET/CT.","authors":"Joseph Hoang, Kyrionna Golliday, Ashtyn McAdoo, Adam Rosenberg, Kamal Jouad, Eben Rosenthal, Michael C Topf","doi":"10.2967/jnumed.125.271333","DOIUrl":"https://doi.org/10.2967/jnumed.125.271333","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing ¹⁷⁷Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses.","authors":"Kyle Flannery, Paul F Cavanaugh, Kevin Steele","doi":"10.2967/jnumed.126.272999","DOIUrl":"https://doi.org/10.2967/jnumed.126.272999","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Conversation Between Stefano Fanti and Johannes Czernin.","authors":"Stefano Fanti, Johannes Czernin","doi":"10.2967/jnumed.126.273735","DOIUrl":"https://doi.org/10.2967/jnumed.126.273735","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective, Single-Center, Single-Arm, Exploratory Study of ¹⁷⁷Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.","authors":"Wei Guo, Chunlei Fan, Yuhang Chen, Shan Yu, Guanming Yue, Tianzhi Zhao, Dan Ruan, Weizhi Xu, Hao Fu, Bishan Su, Lingyu Yu, Liang Zhao, Jingxiong Huang, Hua Wu, Jingjing Zhang, Xin Zhao, Xiaoyuan Chen, Haojun Chen","doi":"10.2967/jnumed.126.272607","DOIUrl":"https://doi.org/10.2967/jnumed.126.272607","url":null,"abstract":"<p><p>Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of ¹⁷⁷Lu-LNC1010-an optimized, long-acting somatostatin analog-in patients with progressive metastatic NETs. <b>Methods:</b> Twenty-two patients with unresectable, metastatic NETs and disease progression despite treatment with somatostatin analogs or tyrosine kinase inhibitors were enrolled in the study. Participants received up to 4 cycles of PRRT with ¹⁷⁷Lu-LNC1010 (3.3 GBq/cycle) at 8-wk intervals. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. The treatment response was evaluated using RECIST 1.1. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). <b>Results:</b> The patients (13 men, 9 women; median age, 50.5 y) received 69 PRRT cycles in total. Treatment-related grade 3 or 4 hematologic toxicities were observed in 6 patients (27%). No grade 3 or higher nephrotoxicity or hepatotoxicity was recorded. The median absorbed tumor dose was 2.12 (interquartile range: 1.68-2.96) Gy/GBq. Response after PRRT was assessed in 18 patients. A partial response was achieved in 8 patients (44.0%), stable disease in 9 (50.0%), and progressive disease in 1 (5.6%). The objective response rate was 44.4%, and the disease control rate was 94.4%. After a median follow-up of 21.0 mo, the median PFS was 15.0 mo, and the median OS was not reached. <b>Conclusion:</b> PRRT with 3.3 GBq/cycle of ¹⁷⁷Lu-LNC1010 was well-tolerated and exhibited an acceptable safety profile. The objective response rate and disease control rate were high and positively correlated with improved PFS and OS. Appropriate patient selection and earlier intervention may further optimize the therapeutic benefit.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}